Tengion Inc. Raises $74 Million for Organ Programs

Published: Aug 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tengion Inc. raises $74.3 million to back its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs. Tengion (NSDQ:TNGN) said it raised $74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces. The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients' own cells.

Help employers find you! Check out all the jobs and post your resume.

Back to news